CDHR2过表达通过抑制PI3K/Akt通路抑制乳腺癌细胞增殖

doi:10.12122/j.issn.1673-4254.2024.06.12

南方医科大学学报 ›› 2024, Vol. 44 ›› Issue (6): 1117-1125.doi: 10.12122/j.issn.1673-4254.2024.06.12

• • 上一篇

CDHR2过表达通过抑制PI3K/Akt通路抑制乳腺癌细胞增殖

房锦存¹^,²^,³(), 刘立威², 林俊豪¹(), 陈逢生¹^,³()

^1.南方医科大学中西医结合医院肝病科，广东广州 510315
^2.南方医科大学附属何贤纪念医院肿瘤科，广东广州 511400
^3.南方医科大学第三临床医学院，广东广州 510630

收稿日期:2023-11-09 出版日期:2024-06-20 发布日期:2024-07-01
通讯作者: 林俊豪,陈逢生 E-mail:fangjincun@126.com;l_i_n@163.com;fsc0126@163.com
作者简介:房锦存，硕士，主治医师，E-mail: fangjincun@126.com
基金资助:
国家自然科学基金(81872251);广东省自然科学基金(2020A1515010093);南方医科大学中西医结合医院院长基金(1202102002)

Overexpression of CDHR2 inhibits proliferation of breast cancer cells by inhibiting the PI3K/Akt pathway

Jincun FANG¹^,²^,³(), Liwei LIU², Junhao LIN¹(), Fengsheng CHEN¹^,³()

^1.Hepatic Department, Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine, Southern Medical University, Guangzhou 510315, China
^2.Department of Oncology, Hexian Memorial Affiliated Hospital of Southern Medical University, Guangzhou 511400, China
^3.Third School of Clinical Medicine, Southern Medical University, Guangzhou 510630, China

Received:2023-11-09 Online:2024-06-20 Published:2024-07-01
Contact: Junhao LIN, Fengsheng CHEN E-mail:fangjincun@126.com;l_i_n@163.com;fsc0126@163.com
Supported by:
National Natural Science Foundation of China(81872251)

摘要/Abstract

摘要：

目的研究CDHR2通过PI3K/Akt信号通路抑制乳腺癌细胞生长和细胞周期的作用机制。方法利用生物信息学分析CDHR2在乳腺癌中的表达及生存预后情况，并利用免疫组化验证，采用qRT-PCR、Western blot检测5株乳腺癌细胞株与正常乳腺上皮细胞中CDHR2的表达，并分析CDHR2的表达情况。筛选出CDHR2表达量低的乳腺癌细胞系MDA-MB-231及MCF7进行质粒转染过表达CDHR2，分为NC组（空白质粒对照）和CDHR2组（CDHR2质粒过表达组）。利用CCK-8增殖实验、EdU增殖实验及细胞周期实验探究CDHR2对乳腺癌细胞生长和细胞周期的影响，通过Western blotting检测CDHR2过表达对PI3K/Akt信号通路和周期通路蛋白表达的影响。结果生物信息学分析显示在乳腺癌及癌旁中CDHR2表达量均较低且两者间差异无统计学意义（P>0.05），但高表达CDHR2乳腺癌患者预后更好（P<0.05）。免疫组化、qRT-PCR及Western blot实验提示，CDHR2在乳腺癌组织及乳腺癌细胞中表达均显著下调（P<0.01），CDHR2可以抑制乳腺癌细胞增殖及阻滞乳腺癌细胞的细胞周期（P<0.01），CDHR2能够抑制PI3K和Akt磷酸化蛋白表达、抑制周期蛋白Cyclin D1的表达。结论过表达CDHR2可能通过PI3K/Akt信号通路抑制乳腺细胞生长及阻滞乳腺癌细胞的细胞周期。

关键词: 乳腺癌, CDHR2, PI3K/Akt通路, 增殖, 细胞周期

Abstract:

Objective To investigate the mechanism by which CDHR2 overexpression inhibits breast cancer cell growth and cell cycle pragression via the PI3K/Akt signaling pathway. Methods Bioinformatic analysis was performed to investigate CDHR2 expression in breast cancer and its correlation with survival outcomes of the patients. Immunohistochemistry was used to examine CDHR2 expressions in surgical specimens of tumor and adjacent tissues from 10 patients with breast cancer. CDHR2 expression levels were also detected in 5 breast cancer cell lines and a normal human mammary epithelial cell line using qRT-PCR and Western blotting. Breast cancer cell lines MDA-MB-231 and MCF7 with low CDHR2 expression were transfected with a CDHR2-overexpressing plasmid, and the changes in cell proliferation and cell cycle were evaluated using CCK-8 assay, EdU assay, and cell cycle assay; the changes in expressions of PI3K/Akt signaling pathway and cell cycle pathway proteins were detected with Western blotting. Results Bioinformatic analysis showed low CDHR2 expression level in both breast cancer and adjacent tissues without significant difference between them (P>0.05), but breast cancer patients with a high expression of CDHR2 had a more favorable prognosis. Immunohistochemistry, qRT-PCR and Western blotting showed that the expression of CDHR2 was significantly down-regulated in breast cancer tissues and breast cancer cells (P<0.01), and its overexpression strongly inhibited cell proliferation, caused cell cycle arrest, and significantly inhibited PI3K and Akt phosphorylation and the expression of cyclin D1. Conclusion Overexpression of CDHR2 inhibits proliferation and causes cell cycle arrest in breast cancer cells possibly by inhibiting the PI3K/Akt signaling pathway.

Key words: breast cancer, CDHR2, PI3K/Akt pathway, proliferation, cell cycle

房锦存, 刘立威, 林俊豪, 陈逢生. CDHR2过表达通过抑制PI3K/Akt通路抑制乳腺癌细胞增殖[J]. 南方医科大学学报, 2024, 44(6): 1117-1125.

Jincun FANG, Liwei LIU, Junhao LIN, Fengsheng CHEN. Overexpression of CDHR2 inhibits proliferation of breast cancer cells by inhibiting the PI3K/Akt pathway[J]. Journal of Southern Medical University, 2024, 44(6): 1117-1125.

图/表 11

图1 TCGA数据集分析CDHR2在乳腺癌及癌旁中表达水平

Fig.1 Analysis of CDHR2 expression levels in breast cancer and adjacent tissues based on TCGA dataset.

图2 CDHR2在乳腺癌患者中的生存预后

Fig.2 Survival outcomes of breast cancer patients with low and high CDHR2 expressions. A-D: Relationship between CDHR2 expression and prognosis of the patients with triple-negative (A), luminal A (B), luminal B (C), and Her2-overexpressing (D) breast cancer, respectively.

图3 组织中评估CDHR2 的免疫组织化学(IHC)染色强度

Fig.3 Fig. 3 Immunohistochemical staining for CDHR2 in clinical specimens of breast cancer tissues (Original magnification: ×400). A: Strong expression of CDHR2 in breast tissues. B: Weak expression of CDHR2 in breast tissues. C: Strong expression of CDHR2 in breast cancer tissues. D: Weak expression of CDHR2 in breast cancer tissues. ****P<0.0001.

图4 乳腺癌细胞系以及正常人乳腺上皮细胞中CDHR2的mRNA表达水平

Fig.4 CDHR2 mRNA expression levels in breast cancer cell lines and normal human mammary epithelial cells. **P<0.01, ***P<0.001 vs MCF10A.

图5 乳腺癌细胞系以及正常人乳腺上皮细胞中CDHR2的蛋白表达水平及统计学分析

Fig.5 CDHR2 protein expression levels in breast cancer cell lines and normal human mammary epithelial cells detected by Western blotting. ***P<0.001 vs MCF10A.

图6 过表达质粒转染MDA-MB-231和MCF7细胞系

Fig.6 CDHR2 mRNA expression in MDA-MB-231 and MCF7 cells transfected with CDHR2-overexpressing plasmids. ***P<0.001.

图7 乳腺癌细胞系中CCK-8细胞增殖实验

Fig. 7 CCK-8 cell proliferation assay of the transfected breast cancer cell lines. **P<0.01, ***P<0.001.

图8 乳腺癌细胞系中EdU细胞增殖实验

Fig.8 EdU proliferation assay of the transfected breast cancer cell lines. **P<0.01.

图9 乳腺癌细胞系中细胞周期实验

Fig.9 Flow cytometry for cell cycle analysis of the transfected breast cancer cell lines. **P<0.01.

图10 Western blotting检测CDHR2对PI3K/Akt信号通路和Cyclin D1蛋白表达影响及统计学分析

Fig.10 Western blotting of PI3K/Akt signaling pathway proteins and cyclin D1 in the transfected cells. ***P<0.001, ****P<0.0001 vs negetive control (NC).

图11 分析CDHR2可能存在相互结合作用的蛋白

Fig.11 Proteins with possible binding sites for CDHR2.

参考文献 30

1	Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48.
2	Kawiak A. Molecular research and treatment of breast cancer[J]. Int J Mol Sci, 2022, 23(17): 9617.
3	An JS, Peng C, Tang HL, et al. New advances in the research of resistance to neoadjuvant chemotherapy in breast cancer[J]. Int J Mol Sci, 2021, 22(17): 9644.
4	Barzaman K, Karami J, Zarei Z, et al. Breast cancer: biology, biomarkers, and treatments[J]. Int Immunopharmacol, 2020, 84: 106535.
5	Pancho A, Aerts T, Mitsogiannis MD, et al. Protocadherins at the crossroad of signaling pathways[J]. Front Mol Neurosci, 2020, 13: 117.
6	Yu JS, Koujak S, Nagase S, et al. PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer[J]. Oncogene, 2008, 27(34): 4657-65.
7	Harada H, Miyamoto K, Yamashita Y, et al. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer[J]. Cancer Med, 2015, 4(10): 1536-46.
8	Haruki S, Imoto I, Kozaki KI, et al. Frequent silencing of protocadherin 17, a candidate tumour suppressor for esophageal squamous cell carcinoma[J]. Carcinogenesis, 2010, 31(6): 1027-36.
9	Fang S, Huang SF, Cao J, et al. Silencing of PCDH10 in hepatocellular carcinoma via de novo DNA methylation independent of HBV infection or HBX expression[J]. Clin Exp Med, 2013, 13(2): 127-34.
10	Lei SY, Zheng RS, Zhang SW, et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020[J]. Cancer Commun, 2021, 41(11): 1183-94.
11	Chodosh LA. Breast cancer: current state and future promise[J]. Breast Cancer Res, 2011, 13(6): 113.
12	McDonald ES, Clark AS, Tchou J, et al. Clinical diagnosis and management of breast cancer[J]. J Nucl Med, 2016, 57(): 9S-16S.
13	Griguolo G, Pascual T, Dieci MV, et al. Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer[J]. J Immunother Cancer, 2019, 7(1): 90.
14	Vega-Benedetti AF, Loi E, Moi L, et al. Clustered protocadherins methylation alterations in cancer[J]. Clin Epigenetics, 2019, 11(1): 100.
15	Imoto I, Izumi H, Yokoi S, et al. Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers[J]. Cancer Res, 2006, 66(9): 4617-26.
16	Wang CL, Yu GZ, Liu JC, et al. Downregulation of PCDH9 predicts prognosis for patients with glioma[J]. J Clin Neurosci, 2012, 19(4): 541-5.
17	Zhen YL, Pavez M, Li XY. The role of Pcdh10 in neurological disease and cancer[J]. J Cancer Res Clin Oncol, 2023, 149(10): 8153-64.
18	Xia ZY, Huang MJ, Zhu QQ, et al. Cadherin related family member 2 acts As A tumor suppressor by inactivating AKT in human hepatocellular carcinoma[J]. J Cancer, 2019, 10(4): 864-73.
19	Okazaki N, Takahashi N, Kojima SI, et al. Protocadherin LKC, a new candidate for a tumor suppressor of colon and liver cancers, its association with contact inhibition of cell proliferation[J]. Carcinogenesis, 2002, 23(7): 1139-48.
20	Ose R, Yanagawa T, Ikeda S, et al. PCDH24-induced contact inhibition involves downregulation of beta-catenin signaling[J]. Mol Oncol, 2009, 3(1): 54-66.
21	Luo J, Yao JF, Deng XF, et al. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling[J]. J Exp Clin Cancer Res, 2018, 37(1): 23.
22	Spangle JM, Dreijerink KM, Groner AC, et al. PI3K/AKT signaling regulates H3K4 methylation in breast cancer[J]. Cell Rep, 2016, 15(12): 2692-704.
23	Xu JC, Chen TY, Liao LT, et al. NETO2 promotes esophageal cancer progression by inducing proliferation and metastasis via PI3K/AKT and ERK pathway[J]. Int J Biol Sci, 2021, 17(1): 259-70.
24	Wang Q, He GP, Hou MM, et al. Cell cycle regulation by alternative polyadenylation of CCND1[J]. Sci Rep, 2018, 8(1): 6824.
25	Hermosilla VE, Salgado G, Riffo E, et al. SALL2 represses cyclins D1 and E1 expression and restrains G1/S cell cycle transition and cancer-related phenotypes[J]. Mol Oncol, 2018, 12(7): 1026-46.
26	Feng YF, Qian WW, Zhang Y, et al. CDCA2 promotes the proliferation of colorectal cancer cells by activating the AKT/CCND1 pathway in vitro and in vivo [J]. BMC Cancer, 2019, 19(1): 576.
27	Xie ZZ, Li W, Ai JG, et al. C2orf40 inhibits metastasis and regulates chemo-resistance and radio-resistance of nasopharyngeal carcinoma cells by influencing cell cycle and activating the PI3K/AKT/mTOR signaling pathway[J]. J Transl Med, 2022, 20(1): 264.
28	Zhong Y, Yang LT, Xiong F, et al. Long non-coding RNA AFAP1-AS1 accelerates lung cancer cells migration and invasion by interacting with SNIP1 to upregulate c-Myc[J]. Signal Transduct Target Ther, 2021, 6(1): 240.
29	Kar G, Gursoy A, Keskin O. Human cancer protein-protein interaction network: a structural perspective[J]. PLoS Comput Biol, 2009, 5(12): e1000601.
30	Cho HJ, Hwang YS, Yoon J, et al. EphrinB1 promotes cancer cell migration and invasion through the interaction with RhoGDI1[J]. Oncogene, 2018, 37(7): 861-72.

[1]	崔芝, 马萃娇, 王倩茹, 陈金豪, 严子阳, 杨建林, 吕亚丰, 曹春雨. 表达 TGF-βⅡ受体的腺相关病毒载体抑制小鼠三阴性乳腺癌4T1细胞的增殖和肺转移[J]. 南方医科大学学报, 2024, 44(5): 818-826.
[2]	王妍, 阮毓卿, 崔璨, 王秀. 交泰丸通过激活PI3K/AKT信号通路改善阿尔茨海默病模型小鼠大脑的葡萄糖代谢[J]. 南方医科大学学报, 2024, 44(5): 894-903.
[3]	夏勇生, 王炼, 陈孝华, 张雨路, 孙奥飞, 陈德利. 过表达TSR2通过下调PI3K/AKT信号通路抑制胃癌细胞的增殖和侵袭[J]. 南方医科大学学报, 2024, 44(5): 913-919.
[4]	王沁智, 宋冰, 郝诗睿, 肖志远, 金连辉, 郑通, 柴芳. 基于生物信息学分析CCND2在甲状腺乳头状癌中的表达及其对免疫浸润的影响[J]. 南方医科大学学报, 2024, 44(5): 981-988.
[5]	黄秋虎, 周建, 王子珍, 杨堃, 陈政纲. miR-26b-3p 靶向 CREB1 调控神经胶质瘤细胞的增殖、迁移及侵袭[J]. 南方医科大学学报, 2024, 44(3): 578-584.
[6]	朱瑾, 欧阳欣, 刘屿, 钱叶梅, 夏斌, 施延安, 俞力夫. miR-132-3p/CAMTA1对I-125粒子处理的面神经损伤大鼠施万细胞的调控作用[J]. 南方医科大学学报, 2024, 44(3): 571-577.
[7]	沈梦迪, 赵娜, 邓晓晶, 邓敏. COX6B2在胃癌组织中高表达并影响患者的远期预后：基于抑制p53信号调控胃癌细胞的增殖及细胞周期[J]. 南方医科大学学报, 2024, 44(2): 289-297.
[8]	王娟, 杨雯钦, 刘进, 石金凤, 肖萍, 李美香. 脂联素通过上调PPARα/HOXA10通路改善多囊卵巢综合征大鼠的子宫内膜容受性[J]. 南方医科大学学报, 2024, 44(2): 298-307.
[9]	张诺, 张震, 张雨路, 宋雪, 张小凤, 李静, 左芦根, 胡建国. PCID2在胃癌组织中高表达并通过调控细胞周期进程和增殖影响患者预后[J]. 南方医科大学学报, 2024, 44(2): 324-332.
[10]	刘雪柔, 杨玉梅, 蔡慧, 张耀帅, 范方田, 李娴, 李姗姗. 阿美替尼具有较好的抗神经母细胞瘤作用：基于下调MMP2和MMP9的表达[J]. 南方医科大学学报, 2023, 43(9): 1493-1499.
[11]	王炼, 夏勇生, 张震, 刘馨悦, 施金冉, 王月月, 李静, 张小凤, 耿志军, 宋雪, 左芦根. 高表达MRPL13促进胃癌细胞增殖并影响患者预后：基于抑制p53信号[J]. 南方医科大学学报, 2023, 43(9): 1558-1566.
[12]	徐梦歧, 石宇彤, 刘俊平, 吴敏敏, 张凤梅, 何志强, 唐敏. JAG1影响单核-巨噬细胞重塑三阴性乳腺癌转移前微环境：基于外泌体中的LncRNA MALAT1[J]. 南方医科大学学报, 2023, 43(9): 1525-1535.
[13]	许家铭, 林龙, 陈琼慧, 李兰. Hsa-miR-148a-3p通过下调DUSP1基因促进乳腺癌细胞的恶性行为[J]. 南方医科大学学报, 2023, 43(9): 1515-1524.
[14]	于正涛, 李佳梦, 蒋俊文, 李由, 林珑, 夏鹰, 王磊. miRNA-128-3p通过下调KLHDC8A的表达抑制胶质瘤细胞的恶性生物学行为[J]. 南方医科大学学报, 2023, 43(9): 1447-1459.
[15]	张晓林, 吴浩松, 汪盛. SLC12A8通过JAK/STAT途径促进膀胱癌细胞的增殖、侵袭与迁移并触发上皮间充质转化[J]. 南方医科大学学报, 2023, 43(9): 1613-1621.

CDHR2过表达通过抑制PI3K/Akt通路抑制乳腺癌细胞增殖

Overexpression of CDHR2 inhibits proliferation of breast cancer cells by inhibiting the PI3K/Akt pathway

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 11

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价